Skip to content

Merck & Co. MRK Additional Paid-In Capital

Additional Paid-In Capital at other companies

Phibro Animal Health logo
Phibro Animal HealthPAHC
$138.18M+1.0%
Cytokinetics logo
CytokineticsCYTK
United Therapeutics logo
United TherapeuticsUTHR
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE

Other financials

Income statement

See full
Revenue$16.3B+4.9%
Gross profit$12.1B-0.2%
Net income-$4.2B-183%
EPS (diluted)-$1.72-186%

Balance sheet

See full
Cash & equivalents$5.4B-38.2%
Total debt$49.1B+35.8%
Total equity$45.9B-5.1%
Total assets$128.69B+11.8%

Cash flow

See full
Operating cash flow$3.9B+56.7%
CapEx$991.0M-25.4%
Free cash flow$2.9B+150%

Valuation

See full
Market cap$317.37B+60.3%
Enterprise value$361.07B+59.3%
P/E35.5×+23.5×
P/S4.8×+1.7×

Profitability

See full
Gross margin73.9%-2.5pp
Net margin13.6%-13.7pp
FCF margin21.5%-5.2pp

Returns & leverage

See full
Return on equity19%-20.3pp
Debt / equity1.1×+0.3×
Current ratio1.3×-0.1×

Where this comes from

Reported directly by Merck & Co. in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: Merck & Co.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Merck & Co.'s additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Merck & Co.'s additional paid-in capital?
Merck & Co. (MRK) reported additional paid-in capital of $45.18B in Q1 2026.
How has Merck & Co.'s additional paid-in capital changed year-over-year?
Merck & Co.'s additional paid-in capital increased by 0.8% year-over-year, from $44.82B to $45.18B.
What is the long-term trend for Merck & Co.'s additional paid-in capital?
Over 5 years (2020 to 2025), Merck & Co.'s additional paid-in capital has grown at a 2.6% compound annual growth rate (CAGR), from $39.59B to $45.03B.
What does additional paid-in capital mean?
This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.